These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 33295805)
1. Will evinacumab become the standard treatment for homozygous familial hypercholesterolemia? Doggrell SA Expert Opin Biol Ther; 2021 Mar; 21(3):299-302. PubMed ID: 33295805 [No Abstract] [Full Text] [Related]
2. Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia. Béliard S; Saheb S; Litzler-Renault S; Vimont A; Valero R; Bruckert É; Farnier M; Gallo A Arterioscler Thromb Vasc Biol; 2024 Jun; 44(6):1447-1454. PubMed ID: 38695169 [TBL] [Abstract][Full Text] [Related]
4. Lessons learned from the evinacumab trials in the treatment of homozygous familial hypercholesterolemia. Khoury E; Croteau L; Lauzière A; Gaudet D Future Cardiol; 2022 Jun; 18(6):507-518. PubMed ID: 35469449 [TBL] [Abstract][Full Text] [Related]
5. Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia. Pirillo A; Catapano AL Expert Opin Biol Ther; 2022 Jul; 22(7):813-820. PubMed ID: 35698895 [TBL] [Abstract][Full Text] [Related]
6. Evinacumab for the treatment of homozygous familial hypercholesterolemia. Gao Y; Zhang B; Yang J Expert Rev Clin Pharmacol; 2022 Feb; 15(2):139-145. PubMed ID: 35220876 [TBL] [Abstract][Full Text] [Related]
9. Evinacumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygous Familial Hypercholesterolemia. White RT; Sankey KH; Nawarskas JJ Cardiol Rev; 2024 Mar-Apr 01; 32(2):180-185. PubMed ID: 37071085 [TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and exposure-response modeling for evinacumab in homozygous familial hypercholesterolemia. Pu X; Sale M; Yang F; Zhang Y; Davis JD; Al-Huniti N CPT Pharmacometrics Syst Pharmacol; 2021 Nov; 10(11):1412-1421. PubMed ID: 34585515 [TBL] [Abstract][Full Text] [Related]
11. Evinacumab: First Approval. Markham A Drugs; 2021 Jun; 81(9):1101-1105. PubMed ID: 34003472 [TBL] [Abstract][Full Text] [Related]
16. Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity. Banerjee P; Chan KC; Tarabocchia M; Benito-Vicente A; Alves AC; Uribe KB; Bourbon M; Skiba PJ; Pordy R; Gipe DA; Gaudet D; Martin C Arterioscler Thromb Vasc Biol; 2019 Nov; 39(11):2248-2260. PubMed ID: 31578082 [TBL] [Abstract][Full Text] [Related]
17. The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia. Raal FJ; Rosenson RS; Reeskamp LF; Kastelein JJP; Rubba P; Duell PB; Koseki M; Stroes E; Ali S; Banerjee P; Chan KC; Khilla N; McGinniss J; Pordy R; Zhang Y; Gaudet D JACC Adv; 2023 Nov; 2(9):100648. PubMed ID: 38938723 [TBL] [Abstract][Full Text] [Related]